Bimagrumab: A Tracking Guide for an Activin Receptor Antibody

Bimagrumab is a monoclonal antibody that blocks the activin type II receptors found on both skeletal muscle and fat tissue. Blocking these receptors increases muscle mass while decreasing fat mass, an unusual profile that sets it apart from appetite-driven weight-loss drugs. It is being developed by Eli Lilly and studied both alone and in combination with semaglutide. In the Phase 2 BELIEVE trial, published in Nature Medicine, bimagrumab plus semaglutide produced about 22.1 percent weight loss with roughly 92 percent of that loss coming from fat, while bimagrumab alone increased total lean mass by about 2.5 percent.

Bimagrumab is investigational and not approved. This is an educational tracking guide, not medical advice or a recommendation.

What it does

• Blocks activin type II receptors on muscle and fat
• Reduces fat mass while preserving or adding skeletal muscle
• Complements GLP-1 drugs, whose weight loss otherwise includes lean mass, when combined with semaglutide

Typical protocol shape

In the trials, bimagrumab is given at intervals of several weeks rather than daily, reflecting an antibody's long half-life, and has been studied both by infusion and injection. Combination studies pair it with once-weekly semaglutide. Any dose or interval figures reflect the trial protocol only, not a recommendation.

What to track daily

• Muscle spasms, a prominent side effect of bimagrumab
• Any acne, another reported effect
• If combined with a GLP-1 drug: nausea, vomiting, diarrhea, or constipation
• Resting heart rate

What to track weekly

• Bodyweight, but paired with body composition rather than read alone
• Waist circumference as a fat-loss signal
• Grip strength and a strength benchmark, since preserving or adding muscle is the whole point
• Injection or infusion-site tolerance

Bloodwork and body composition worth doing

• A DEXA or comparable body-composition scan to separate fat loss from muscle change, which is central here
• Fasting glucose and HbA1c, since the drug improves insulin sensitivity
• Lipid panel over time

Realistic expectations

Bimagrumab's appeal is the body-composition split, not raw scale numbers, so tracking weight alone undersells it and can even mislead when muscle is being added. The strongest weight numbers came from the semaglutide combination, which also carries GLP-1 class GI effects.

Common mistakes

• Judging progress by the scale instead of body composition
• Ignoring muscle spasms rather than reporting them
• Assuming the muscle-sparing effect removes the need for resistance training

Safety notes

Bimagrumab is investigational and not approved, with a risk profile still being defined. Muscle spasms and acne were prominent, GI intolerance dominated when combined with semaglutide, and discontinuations were highest on bimagrumab monotherapy. Any non-trial access is outside the evidence base; use only with medical supervision and body-composition monitoring.

Peptid AI is an educational and self-tracking tool. Nothing in this post is medical advice. Doses mentioned reflect what is commonly reported in research literature — they are not recommendations. Always consult a qualified physician before starting, changing, or stopping any protocol.